Report Store Get Proposal

Home Blog Notizia 43

Notizia - Recent Pharma, Healthcare and Biotech Happenings

pharma-biotech-news-updates-for-pfizer-kytopen-eli-lilly-vensana-reify-health

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Pfizer tightens DMD trial criteria over safety concerns; Kytopen raises $30M; Eli Lilly taps Reify’s Care Access; Vensana Capital raises $325M

Pfizer tightens DMD patient criteria after serious adverse events in phase 3 gene therapy trial Pfizer is tightening up the criteria for Duchenne muscular dystrophy patients to partake in phase 3 clinical trials of its experimental gene therapy after three severe events were cropping up in ongoing studies. The New York-based Big Pharma declared the news with the DMD community in a letter for the Parent Project Muscular Dystrophy patient advocacy group. Pfizer said three cases of muscle weakness, including inflammation of the heart tissue called myocarditis, were observed in patients after fordadistrogene movaparvovec treatment. The adverse events were attr...

Explore More...

Companion Diagnostics

Notizia

Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug

Hot flashes

Notizia

COMMERCIAL AND OTHERS

KEY CLINICAL OUTCOMES

FDA

Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray

Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand

Notizia

Johnson & Johnson

Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro loses partner

Johnson & Johnson

Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune

transthyretin amyloidosis

Notizia

Johnson & Johnson

Epic Sciences garners; Tvardi gets financing; Galera raises; Fund for cancer research

transthyretin amyloidosis

Notizia

Johnson & Johnson

Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M

transthyretin amyloidosis

Notizia

Johnson & Johnson

4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly